Hans Eriksson
Helsingborgs lasarett(SE)HolsboerMaschmeyer NeuroChemie (Germany)(DE)AstraZeneca (Germany)(DE)
Publications by Year
Research Areas
Treatment of Major Depression, Bipolar Disorder and Treatment, Schizophrenia research and treatment, Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes, Electroconvulsive Therapy Studies
Most-Cited Works
- → A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia(2015)323 cited
- → CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice(2019)236 cited
- → Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial(2015)179 cited
- → Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study(2010)179 cited
- → Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder(2015)172 cited
- → Remote assessment of disease and relapse in major depressive disorder (RADAR-MDD): a multi-centre prospective cohort study protocol